Last Updated : October 13, 2005
Details
FilesGeneric Name:
Omalizumab
Project Status:
Complete
Therapeutic Area:
Asthma, severe persistent
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Xolair
Project Line:
Reimbursement Review
Project Number:
SR0045-000
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Resubmission
Indications:
Asthma, severe persistent
Recommendation Type:
Do not list
Final Recommendation:
Recommendation:
(tentative)
Files
Last Updated : October 13, 2005